(+)-JQ1

Catalog No.S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 198 Publications

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  M{jGbWNmdGxiVnnhZoltcXS7IFHzd4F6 M1q5dFI2OC93MECvNVAxOCCwTR?= MlX4NlQwPDhxN{KgbC=> NHf6fYNFVVOR MnLybY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MUOyOlcxPzh6MR?=
BCPAP MmPiR4VtdCCYaXHibYxqfHliQYPzZZk> M1TaTlI2OC93MECvNVAxOCCwTR?= NEDNdGQzPC92OD:3NkBp NXjhUJFVTE2VTx?= M4Xx[4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NFj0RpozPjdyN{i4NS=>
K1  MYLD[YxtKEO7Y3zlJGF{e2G7 M3jrOFI2OC93MECvNVAxOCCwTR?= M4nSZ|czKGh? M1ruWWROW09? MmnpZZJz\XO2czDj[YxtKGO7Y3zlJIF1KEdyL1exJJBp[XOn MYiyOlcxPzh6MR?=
BCPAP NHrwOJBE\WyuIFP5Z4xmKEG|c3H5 MlTCNlUxNzVyMD:xNFAxKG6P NV3FU|dTPzJiaB?= MXjEUXNQ NGD5NYpienKnc4TzJINmdGxiY4njcIUh[XRiR{CvS|EheGijc3W= NWXydXNpOjZ5MEe4PFE>
Hep3B M4ixSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M130ZlAuOTBizszN M1HZV|Uh\A>? M{LzWGROW09? MXfJR|UxRTBwMEig{txO NWXKbZJZOjZ3N{WxOlc>
HCCLM3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXrNYFqOC1zMDFOwG0> Mm\1OUBl NGDC[pZFVVOR NFLXWZVKSzVyPUCuNVQh|ryP MkPENlY2PzVzNke=
HuH7 NIHoeJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\QN|AuOTBizszN M1vmVlUh\A>? NEGzN2pFVVOR MWXJR|UxRTBwMkGg{txO NWHLXok2OjZ3N{WxOlc>
HepG2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTXc|NsOC1zMDFOwG0> MnLMOUBl NWjkR3NGTE2VTx?= NGDqVYNKSzVyPUCuN|Qh|ryP MoLkNlY2PzVzNke=
SMMC7721 MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV2wMVExKM7:TR?= NGjUNVA2KGR? NIn2ZYlFVVOR NXX4[mI{UUN3ME2wMlQyKM7:TR?= Mmq4NlY2PzVzNke=
BEL7402 NF7uNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHxcZJDOC1zMDFOwG0> MXq1JIQ> M2L5UGROW09? MVrJR|UxRTBwNEeg{txO M3PlUlI3PTd3MU[3
MHCC97H M3zVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[wMVExKM7:TR?= NY\0fmgxPSCm NGq1[o9FVVOR M{PuRmlEPTB;MD60NUDPxE1? MoPMNlY2PzVzNke=
Hep3B MoHTR4VtdCCFeXPs[UBCe3OjeR?= Mn3lNE4yNzBwNT:yMlUh|ryP NI\r[Zk1QCCq MmXiSG1UVw>? M33scoxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKEiFQzDj[YxteyCrbjDzeYIuTzFicHjhd4XDqA>? M4\ROFI3PTd3MU[3
HCCLM3 MlPxR4VtdCCFeXPs[UBCe3OjeR?= NH7Wb5YxNjFxMD61M|IvPSEQvF2= MUm0PEBp NGD4cVFFVVOR MljscIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhUEOFIHPlcIx{KGmwIIP1Zk1IOSCyaHHz[eKh NXHmXYZnOjZ3N{WxOlc>
Hep3B NXzq[XN7SXCxcITvd4l{KEG|c3H5 NUDmNGt7OC5zL{CuOU8zNjVizszN MlnoOFghcA>? MVvEUXNQ M1vpc4FkfGm4YYTld{Bk[XOyYYPlMVMh[W6mIHPhd5Bie2VvOTDlfJBz\XO|aX;uJIFv\CCrbnT1Z4VlKFCDUmCgZ4xm[X[jZ3WgZZMhf2WubDDhd{BkgXSxY3jyc41mKGNicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21iZoLvcUBucXSxY3jvcoRzcWF? MX6yOlU4PTF4Nx?=
HCCLM3 M1jOXGFxd3C2b4Ppd{BCe3OjeR?= MmS4NE4yNzBwNT:yMlUh|ryP M4rhSFQ5KGh? M4Hac2ROW09? M2PDfoFkfGm4YYTld{Bk[XOyYYPlMVMh[W6mIHPhd5Bie2VvOTDlfJBz\XO|aX;uJIFv\CCrbnT1Z4VlKFCDUmCgZ4xm[X[jZ3WgZZMhf2WubDDhd{BkgXSxY3jyc41mKGNicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21iZoLvcUBucXSxY3jvcoRzcWF? NUTUNI5zOjZ3N{WxOlc>
A549 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT1[lcxNjFvMUCg{txO NH[wZ4E4OiCq M1KweYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NHnPcYMzPjRzNUKyOS=>
H157 M4DHbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPT[GxmOC5zLUGwJO69VQ>? M2PqVlczKGh? M1qwR4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Mn3sNlY1OTV{MkW=
H1299 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\EUFAvOS1zMDFOwG0> MkHCO|IhcA>? NFHjXHBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NUnSUGczOjZ2MUWyNlU>
A549 MmjYSpVv[3Srb36gRZN{[Xl? NW\DbJgyOS9{LkWvOUDPxE1? NX;CVY1POTJiaB?= NUDURY51yqC5ZXHrcJkh\GWlcnXhd4VlKEKlbD2yJIxmfmWucx?= MXuyOlQyPTJ{NR?=
H1299 MonKSpVv[3Srb36gRZN{[Xl? MnPKNU8zNjVxNTFOwG0> NUHCboNHOTJiaB?= M1fiWOKhf2Wja3z5JIRm[3KnYYPl[EBD[2xvMjDs[ZZmdHN? M{i0PFI3PDF3MkK1
H157 MXjGeY5kfGmxbjDBd5NigQ>? NEmycZEyNzJwNT:1JO69VQ>? MWWxNkBp NHW0[oxl\WO{ZXHz[YQhTFJ2IHX4dJJme3Orb36= M1rLSVI3PDF3MkK1
H1299 NHTQWnFHfW6ldHnvckBCe3OjeR?= M4nRUFEwOi53L{Wg{txO NYSzVYY3OTJiaB?= MoXu[IVkemWjc3XkJGRTPCCneIDy[ZN{cW:w NFHBcIgzPjRzNUKyOS=>
C8161 MVrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4LZSVAuOiEQvF2= NVi4[VFVPCCm MVvEUXNQ NH7DW3Nl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NXXoVVVMOjZ|OUeyNlM>
Mel285 M2nXc2NmdGxiVnnhZoltcXS7IFHzd4F6 MnHJNE0zKM7:TR?= MWq0JIQ> NFrRU|ZFVVOR M3zYc4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1O3[lI3Ozl5MkKz
Mel290 Ml\DR4VtdCCYaXHibYxqfHliQYPzZZk> NF7xd48xNTJizszN MlPWOEBl M1TDcmROW09? NHLFfXdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MkXGNlY{QTd{MkO=
92.1 M{jrSmNmdGxiVnnhZoltcXS7IFHzd4F6 M{fWWFAuOiEQvF2= NIfWSJA1KGR? MYLEUXNQ NGnJcWVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NFvKV3gzPjN7N{KyNy=>
Omm1.3 MYjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnzvNE0zKM7:TR?= MmLhOEBl MVPEUXNQ NGm3boll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M{L2[VI3Ozl5MkKz
Mel202 NVnJcohOS2WubDDWbYFjcWyrdImgRZN{[Xl? MlS4NE0zKM7:TR?= NFTXTGc1KGR? NVvzb2xWTE2VTx?= M{O3OIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NXfJ[|IxOjZ|OUeyNlM>
Mel270 NEj4TFJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NEXDOlIxNTJizszN NIC2eI81KGR? NEPkV4dFVVOR MWXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mo\DNlY{QTd{MkO=
Omm1 MmCyR4VtdCCYaXHibYxqfHliQYPzZZk> NXHlS2E4OC1{IN88US=> MXi0JIQ> NEmwW5hFVVOR Mnnl[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MkLmNlY{QTd{MkO=
92.1 M1\ofGFxd3C2b4Ppd{BCe3OjeR?= NF34b2k2ODBibl2= MniwOFghcA>? NXfjXlFNTE2VTx?= MVjpcoR2[2W|IHHwc5B1d3Orcx?= NFeyXIIzPjN7N{KyNy=>
Omm1.3 MUfBdI9xfG:|aYOgRZN{[Xl? Mm\jOVAxKG6P MYi0PEBp Mly4SG1UVw>? MUjpcoR2[2W|IHHwc5B1d3Orcx?= NV7WVmEzOjZ|OUeyNlM>
92.1 MmjJR4VtdCCFeXPs[UBCe3OjeR?= MXS1NFAhdk1? M{TZZVI1NzR6L{eyJIg> NIO2O|lFVVOR NUHMV29xcW6mdXPld{B1cGViY3XscEBi[2O3bYXsZZRqd25iYYSgd5VjNUdzwrC= NHHqR5UzPjN7N{KyNy=>
Omm1.3 NXLxSYZiS2WubDDDfYNt\SCDc4PhfS=> NXTH[|dMPTByIH7N MoW3NlQwPDhxN{KgbC=> NYjzeGI3TE2VTx?= M1XIbIlv\HWlZYOgeIhmKGOnbHygZYNkfW23bHH0bY9vKGG2IIP1Zk1IOcLi NU\RTlBxOjZ|OUeyNlM>
A549 NVrEbGNsTnWwY4Tpc44hSXO|YYm= M{LCW|ExOC92MECvNVAxOCCwTR?= NUXM[mp2OjRiaB?= NE\1blJ2eHKnZ4XsZZRmeyCjbnSgZYN1cX[jdHXzJHNKWlRz NIqwTpIzPjJzMkG5PS=>
MCF-7 NUDFOW5XTnWwY4Tpc44hSXO|YYm= NEDRTnMyODBxNECwM|ExODBibl2= M3TkeFI1KGh? Mm\CeZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>? M{HvWlI3OjF{MUm5
HEK293 MoXISpVv[3Srb36gRZN{[Xl? M4L1eVExOC92MECvNVAxOCCwTR?= MXSyOEBp MnvmeZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>? NV36TmlpOjZ{MUKxPVk>
858 NImwTYRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MkTDNE0yKM7:TR?= M4TWXVUh\A>? M3n0XWROW09? M{nLZ4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHHKdHAzPjJyNkOzNy=>
DDR2L63V M2q3eWNmdGxiVnnhZoltcXS7IFHzd4F6 MXSwMVEh|ryP M3XQUFUh\A>? Mn;HSG1UVw>? NXzOPHhR\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NVS4Z41iOjZ{ME[zN|M>
BE(2)-C NYfhN2w4S2WubDDWbYFjcWyrdImgRZN{[Xl? M2\hVlEh|ryP NUTadFFuOS12IHS= M1n4dIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 NXvEdYtXOjZyNke0OlQ>
IMR-32 MmP2R4VtdCCYaXHibYxqfHliQYPzZZk> MYexJO69VQ>? M4H6OFEuPCCm M2SybYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 NVm4WlBjOjZyNke0OlQ>
JF MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFLkcG4yKM7:TR?= NVnacJZPOS12IHS= M2H1VIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 NXz0OoZlOjZyNke0OlQ>
BE(2)-M17 M1LHcGNmdGxiVnnhZoltcXS7IFHzd4F6 M1\ySFEh|ryP NX\hNFZpOS12IHS= Mnrp[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> NH;sS2EzPjB4N{S2OC=>
SK-N-SH MoT6R4VtdCCYaXHibYxqfHliQYPzZZk> NUnHXpRmOSEQvF2= NWLNeZhpOS12IHS= M1rOR4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 M4DxW|I3ODZ5NE[0
SK-N-DZ  MXrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3\kZlEh|ryP Mn7PNU01KGR? NGrIXIJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? MkfqNlYxPjd2NkS=
HMC-1.1  Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2K1OFUuPTByMDDuUS=> NV[wTWx{PDhiaB?= MkHqSG1UVw>? M2WxfYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NH[wbXkzPjB3NUOwNy=>
HMC-1.2 NX\pTYYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LEdVUuPTByMDDuUS=> MnfPOFghcA>? MkHMSG1UVw>? NUDpbmJ7cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVS4SopNOjZyNUWzNFM>
ROSA KIT WT  M3fpV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\4SZlLPS13MECwJI5O NXXOWppMPDhiaB?= NYPMR4NJTE2VTx?= M4\QdIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Mn\wNlYxPTV|MEO=
ROSA KIT D816V MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXu1MVUxODBibl2= NGS5VWI1QCCq Mle1SG1UVw>? M2qzOIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NHvUdpkzPjB3NUOwNy=>
HMC-1.1  Mn3IRZBweHSxc3nzJGF{e2G7 MV6yNFAuPTByMDDuUS=> NEe5cWU1QCCq M4CyWmROW09? NED5PWlqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NXexc|V6OjZyNUWzNFM>
HMC-1.2 MXPBdI9xfG:|aYOgRZN{[Xl? NIjudVMzODBvNUCwNEBvVQ>? NFj4d4M1QCCq NV7SRYlSTE2VTx?= M4TKWYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYP3fFI3OjZyNUWzNFM>
ROSA KIT WT  MWnBdI9xfG:|aYOgRZN{[Xl? NGnafFQzODBvNUCwNEBvVQ>? MnH6OFghcA>? M1Htd2ROW09? M4TuRYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2qxNFI3ODV3M{Cz
ROSA KIT D816V M1TjVWFxd3C2b4Ppd{BCe3OjeR?= MWeyNFAuPTByMDDuUS=> MlvvOFghcA>? M{XnZmROW09? NFfCclVqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NV3mNYZVOjZyNUWzNFM>
494H NXXVeI5yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDOSWc4OiCq M{XCfGROW09? NUC3PGdwUUN3ME2wMlEzOsLzMD6wNFQh|ryP NHrw[IozPTl2NEW2Oi=>
493H MnPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUG3NkBp M3;HSGROW09? MVfJR|UxRTBwMES3xtExNjByOTFOwG0> NGLEUZYzPTl2NEW2Oi=>
716H NGH3e4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TCPVczKGh? NWCyTlh7TE2VTx?= MULJR|UxRTBwMkGyxtExNjB|NDFOwG0> M{DlUFI2QTR2NU[2
148I NGT4Z2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rGclczKGh? MVfEUXNQ NE[2SYJKSzVyPUCuNlg1yrFyLkCzOUDPxE1? MXmyOVk1PDV4Nh?=
98Sc M3rHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrqO|IhcA>? NVnUdZNCTE2VTx?= M1\mZmlEPTB;MD6xNVXDuTBwMEC0JO69VQ>? NEP3d4ozPTl2NEW2Oi=>
89R NXvmRXE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYi3NkBp M3zsU2ROW09? Mo[4TWM2OD1yLkGyOuKyOC5yMEOg{txO MW[yOVk1PDV4Nh?=
494L MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTsZ45zPzJiaB?= M3XNdGROW09? MVLJR|UxRTBwM{G3xtExNjBzMjFOwG0> NX\0Xop6OjV7NES1OlY>
493L NVXYR|VIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1e2Z|czKGh? M3LyU2ROW09? M4rRS2lEPTB;MD6wOVDDuTBwMEGxJO69VQ>? NWKwSXlmOjV7NES1OlY>
148L NVfYdm0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfpO|IhcA>? M17M[2ROW09? MXjJR|UxRTBwMUS2xtExNjBzNzFOwG0> Mnv5NlU6PDR3Nk[=
98L M2[xfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\odlczKGh? M4\VPGROW09? M1ftTWlEPTB;MD6zNFnDuTBwMEK5JO69VQ>? M3jaOFI2QTR2NU[2
OS17 M1jW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUe3NkBp MX;EUXNQ MlnoTWM2OD1yLkC3PeKyOC5yMEOg{txO NWKyfFg{OjV7NES1OlY>
OS9 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnhdWg4OiCq NFXpZ45FVVOR MnfrTWM2OD1yLkSwOuKyOC5yMkig{txO M2fY[lI2QTR2NU[2
MG63 NF\iWFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV2zOlB6PzJiaB?= MXnEUXNQ M2nVN2lEPTB;MD6xNVTDuTBwMEK1JO69VQ>? MnnwNlU6PDR3Nk[=
SAOS2 NIPMWYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHGcm9GPzJiaB?= MmTWSG1UVw>? M2\4fGlEPTB;MD6yNVfDuTBwMECzJO69VQ>? NVrLNYZYOjV7NES1OlY>
U2OS Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHqyOYQ4OiCq NITZRolFVVOR MlT0TWM2OD1yLkG5POKyOC5yMEig{txO MWOyOVk1PDV4Nh?=
SJSA-1 MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX63NkBp NXX5cGk3TE2VTx?= MXPJR|UxRTBwMUCwxtExNjBzMDFOwG0> NF3MdJkzPTl2NEW2Oi=>
494H NU\IOndRSXCxcITvd4l{KEG|c3H5 NUXHUYNxOC5{NT:wMlUwOS5yIN88US=> MnTGNlQhcA>? NVXOW3FbTE2VTx?= MWnpcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> MlziNlU6PDR3Nk[=
148I NVThVZcySXCxcITvd4l{KEG|c3H5 MnXpNE4zPS9yLkWvNU4xKM7:TR?= MmK1NlQhcA>? M3TvZ2ROW09? NGfITIlqdmO{ZXHz[ZMhdGW4ZXzzJI9nKGOuZXH2[YQh[2G|cHHz[U0{yqB? M4PnW|I2QTR2NU[2
OS17 NGP1Wm5CeG:ydH;zbZMhSXO|YYm= NXfPb49QOC5{NT:wMlUwOS5yIN88US=> M1;rUVI1KGh? NHm5PVdFVVOR MmXTbY5kemWjc3XzJIxmfmWuczDv[kBkdGWjdnXkJINie3Cjc3WtN:Kh M4\FOFI2QTR2NU[2
494H NUTyTWdMSXCxcITvd4l{KEG|c3H5 MlHyNgKBkc7:TR?= MoXyOFghcA>? M33tS2ROW09? MVnpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bIm= M4TyPFI2QTR2NU[2
148I NUTXNYloSXCxcITvd4l{KEG|c3H5 Mn70NgKBkc7:TR?= M3\u[FQ5KGh? MXPEUXNQ NX;wOWVDcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 M{i2NVI2QTR2NU[2
OS17 MWjBdI9xfG:|aYOgRZN{[Xl? Mn7wNgKBkc7:TR?= NGnYZ2o1QCCq MnP2SG1UVw>? NUCzV|d1cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 NWP4ZotEOjV7NES1OlY>
MOLM13 MWHBdI9xfG:|aYOgRZN{[Xl? M17nblI2OCCwTR?= NWDoWJkxPDhiaB?= NHvEe|VFVVOR MU\pcoR2[2W|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheXWrenHyeIlvcWJ? NUfvSHpIOjVyNUO4NlU>
MV4-11  MXfBdI9xfG:|aYOgRZN{[Xl? MVOyOVAhdk1? NIDRe5Q1QCCq NUi0e25nTE2VTx?= M{DWdYlv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCzdXn6ZZJ1cW6rYh?= NUD1[IR2OjVyNUO4NlU>
MOLM13 M3y4dGZ2dmO2aX;uJGF{e2G7 NIXhcIkzPTBibl2= NHz5fmYzPCCq MlSwSG1UVw>? MlnP[Y5p[W6lZYOgdZVqgmG{dHnubYIucW6mdXPl[EBud3KnIICyNUwhSkmPLDDhcoQh[2ynYY\l[EBRSVKS M1fGOFI2ODV|OEK1
MV4-11  NUfEUVJPTnWwY4Tpc44hSXO|YYm= MnfJNlUxKG6P NWTy[WJIOjRiaB?= NU\uZYNzTE2VTx?= MkHz[Y5p[W6lZYOgdZVqgmG{dHnubYIucW6mdXPl[EBud3KnIICyNUwhSkmPLDDhcoQh[2ynYY\l[EBRSVKS NWPacHFnOjVyNUO4NlU>
MOLM13 MmXoRZBweHSxc3nzJGF{e2G7 NX7yV3R4OjVyIH7N NFfNWJc1QCCq NFjZZmtFVVOR M3jt[Ilv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCyb37heIlvcWJ? M{DjTlI2ODV|OEK1
MV4-11  Mn3oRZBweHSxc3nzJGF{e2G7 NG\2[ZYzPTBibl2= MWW0PEBp NHPJWoNFVVOR MlfJbY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHCxbnH0bY5q[g>? MVOyOVA2Ozh{NR?=
Hela M1PXZmNmdGxiVnnhZoltcXS7IFHzd4F6 NUTWPWhKOC13MECgcm0> MXe3NkBp MWHEUXNQ MlnS[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NELqcmgzPTByOUK5OS=>
HBL-1 M1PKO2NmdGxiVnnhZoltcXS7IFHzd4F6 NUPz[|NGOC13MECgcm0> NF3xOmU4OiCq NYHGfI5DTE2VTx?= M{nSV4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFXhZVMzPTByOUK5OS=>
HLY-1 M4m5NmNmdGxiVnnhZoltcXS7IFHzd4F6 MYWwMVUxOCCwTR?= M1jwOlczKGh? NWixRoJwTE2VTx?= MV;k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4XUbFI2ODB7Mkm1
OCI-Ly3 M3\5WWNmdGxiVnnhZoltcXS7IFHzd4F6 MmHDNE02ODBibl2= NXPNRWZ1PzJiaB?= NIT4d|VFVVOR M3r4VYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NI\D[mUzPTByOUK5OS=>
OCI-Ly10 MnH2R4VtdCCYaXHibYxqfHliQYPzZZk> NIHEVXUxNTVyMDDuUS=> M361NVczKGh? NEfvVWZFVVOR NYjTVoVP\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MoraNlUxODl{OUW=
SU-DHL-4 M2\vfmNmdGxiVnnhZoltcXS7IFHzd4F6 NFLn[4gxNTVyMDDuUS=> M3HDT|czKGh? NX23O3lxTE2VTx?= M1WwcoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MmfCNlUxODl{OUW=
SU-DHL-5 NIPtclJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1Tve|AuPTByIH7N NXH3ZZVyPzJiaB?= M2G1TGROW09? NEm1SWxl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M3vkPFI2ODB7Mkm1
SU-DHL-6 M4f6c2NmdGxiVnnhZoltcXS7IFHzd4F6 MmDHNE02ODBibl2= NILvV5M4OiCq NVOyeVZUTE2VTx?= NV\4VYJy\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NHjveHozPTByOUK5OS=>
SU-DHL-10 NF3rWmpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVOwMVUxOCCwTR?= MmH5O|IhcA>? NWjRPYlFTE2VTx?= MXrk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYPiUplJOjVyMEmyPVU>
RC-K8 MXjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NH2yTGcxNTVyMDDuUS=> NFKzTG84OiCq MmDPSG1UVw>? NVvVcWdw\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFPFN5YzPTByOUK5OS=>
OCI-Ly8 M1XyfGNmdGxiVnnhZoltcXS7IFHzd4F6 NYGyWIdsOC13MECgcm0> MlfwO|IhcA>? NU\sR4hWTE2VTx?= MoLX[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M4fodVI2ODB7Mkm1
OCL-Ly18 MYTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1XOUlAuPTByIH7N M3\PeVczKGh? MUjEUXNQ MnXH[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NYrOSVdYOjVyMEmyPVU>
OCI-Ly3 Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkKwNVczNzJ3MD:1NFAhdk1? NGT1bY4zNzdiZB?= M3rpbGROW09? M37Fdolv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC= MWOyOVAxQTJ7NR?=
OCI-Ly8 M1HY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\JNVczNzJ3MD:1NFAhdk1? NXzM[VRMOi95IHS= MX\EUXNQ M1\Feolv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC= NVPZb3RlOjVyMEmyPVU>
SU-DHL-4 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWWxO|IwOjVyL{WwNEBvVQ>? MX2yM|ch\A>? M3TlRmROW09? NVzFTI5VcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC|dXKtS|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=> M3\i[|I2ODB7Mkm1
SU-DHL-10 NIm0S2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\4NVczNzJ3MD:1NFAhdk1? NUnDfJhLOi95IHS= M{PL[2ROW09? M1fzPIlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC= NVO5fINiOjVyMEmyPVU>
OCI-Ly3 Mn7FRZBweHSxc3nzJGF{e2G7 NGnTZWYyPzJxMkWwJI5O MV23[C=> NWfFSWp2TE2VTx?= NVXBW3RLcW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6 NVnVfnpIOjVyMEmyPVU>
OCI-Ly8 NWS2T2ZtSXCxcITvd4l{KEG|c3H5 NUfYVFZ[OTd{L{K1NEBvVQ>? NIGzPYE4\A>? NGTuVolFVVOR MVzpcoNz\WG|ZYOgZ4F{eGG|ZT2zM|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm= M3niWFI2ODB7Mkm1
SU-DHL-4 M4DTfWFxd3C2b4Ppd{BCe3OjeR?= NIHKS2EyPzJxMkWwJI5O NEDVe2k4\A>? NWLvOYVmTE2VTx?= M3HXPIlv[3KnYYPld{Bk[XOyYYPlMVMwPyCjY4Tpeol1gcLic3nncolncWOjboTsfS=> NYnPbXpDOjVyMEmyPVU>
SU-DHL-10 M4jqbmFxd3C2b4Ppd{BCe3OjeR?= NHfXZlEyPzJxMkWwJI5O MWq3[C=> M3v3[GROW09? NYPuZ|NCcW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6 MkKyNlUxODl{OUW=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pDNA-PKcs / γH2AX / Ub-γH2AX / p-c-Jun S63 / Bax; 

PubMed: 26119999     


The comparative effects of the active (+)-JQ1 vs. the inactive (−)-JQ1 on the cellular responsiveness to radiation and the cell fate decision. 

c-Myc; 

PubMed: 23792448     


PEL and non-PEL (Namalwa) cells treated with indicated doses of (+)-JQ1 for 48 hours were lysed and analyzed by Western blot for the expression of c-Myc. GAPDH was used as a loading control. 

p27; 

PubMed: 23792448     


Western blot analysis showing induction of p27 upon 48 hours of treatment with (+)-JQ1. GAPDH serves as a loading control.

26119999 23792448
Growth inhibition assay
Cell viability; 

PubMed: 23792448     


PEL cell lines (BC1, BC3, BCBL1 and JSC1) were treated with indicated doses of (-)-JQ1 or (+)-JQ1 for 5 days and cell viability measured using an MTS assay (refer to Materials and methods). Namalwa, a Burkitt's lymphoma cell line, was used as a control. 

23792448
Immunofluorescence
GM130; 

PubMed: 29074567     


Representative images of A549cells treated with single compounds or in combination (as indicated) are shown. 

MHC / EdU; 

PubMed: 28733670     


C2C12 cultures were switched to DM and treated with 1 µM (+)-JQ1, (−)-JQ1, DMSO or untreated (DM only). Cells were fixed at 12, 24, 48 and 72 hours after treatment and pulsed with EdU 2 hours before fixation. EdU positive nuclei were stained with Alexa Fluor 555 and cultures immunostained for MHC.

29074567 28733670
In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Mice bearing NMC 797 xenografts
  • Formulation: 5% DMSO in 5% dextrose
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the compound for in vivo injection?

  • Answer:

    JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID